In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Impact of physicians' adherence to guideline-recommended therapy on heart failure re-hospitalizations: data from the Optimize Heart Failure Care Program

Session Patient management - From oral treatment to transplant

Speaker Anna Grebennikova

Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Treatment, Other
  • Session type : Rapid Fire Abstracts
  • FP Number : 1537

Authors : Y M Lopatin (Volgograd,RU), A Grebennikova (Volgograd,RU), H Sisakian (Yerevan,AM), H Hayrapetyan (Yerevan,AM), Z Pagava (Tbilisi,GE), T Abdullaev (Tashkent,UZ), G Dadashova (Baku,AZ), S Berkinbayev (Almaty,KZ), A Rakisheva (Almaty,KZ), A Chesnikova (Rostov-on-Don,RU), E Tarlovskaya (Nizhny Novgorod,RU), Z Kipiani (Tbilisi,GE), N Koziolova (Perm,RU), V Tseluyko (Kharkiv,UA), L Voronkov (Kiev,UA)

15 views

Authors:
Y M Lopatin1 , A Grebennikova1 , H Sisakian2 , H Hayrapetyan3 , Z Pagava4 , T Abdullaev5 , G Dadashova6 , S Berkinbayev7 , A Rakisheva7 , A Chesnikova8 , E Tarlovskaya9 , Z Kipiani10 , N Koziolova11 , V Tseluyko12 , L Voronkov13 , 1Volgograd State Medical University, Volgograd Regional Cardiology Centre - Volgograd - Russian Federation , 2Yerevan State Medical University Hospital 1: University Cardiology Clinic - Yerevan - Armenia , 3Erebouni Medical Center - Yerevan - Armenia , 4Centre of Vascular and Heart Diseases - Tbilisi - Georgia Republic of , 5Specialized Cardiology Center of the Republic of Uzbekistan - Tashkent - Uzbekistan , 6Scientific Research Institute of Cardiology - Baku - Azerbaijan , 7Scientific Research Institute of Cardiology and Internal Diseases - Almaty - Kazakhstan , 8State Medical University of Rostov-on-Don - Rostov-on-Don - Russian Federation , 9Nizhny Novgorod State Medical Academy - Nizhny Novgorod - Russian Federation , 10“New Hospital” - Tbilisi - Georgia Republic of , 11Perm State Medical Academy - Perm - Russian Federation , 12Kharkiv National Academy of Postgraduate Education - Kharkiv - Ukraine , 13NSC Institute of Cardiology M.D. Strazhesko - Kiev - Ukraine ,

Citation:

Background. In spite of the evidence that good adherence to guidelines can improve clinical outcomes many studies demonstrate suboptimal implementation of guideline-based heart failure (HF) treatment into real clinical practice. The aim of our study was to evaluate the impact of physicians’ adherence to guideline-recommended therapy on the rate of HF re-hospitalizations at 12-months of follow-up.

Methods.  This study was part of an international multicenter Optimize Heart Failure Care Program and included 740 patients hospitalized due to worsening HF (mean age 61.9 ± 11.8 years, 70% male, 77.7% with sinus rhythm, NYHA II-IV, mean 2.7 ± 0.6, mean LVEF 35.1 ± 9.9%). To assess physicians’ adherence to the medications recommended by the 2016 ESC HF guidelines, a five-class guideline adherence score for angiotensin converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and ivabradine was used.
The score was calculated for each patient by summing the points: 0 for non-prescription of medication in the absence of contraindications and one point each for the use of ACEIs/ARBs, BBs, MRAs and ivabradine.  Three types of adherence were defined: good adherence (use of all guideline-recommended medications; score=1); moderate adherence (use of >50% recommended medications; score >0.5-<1); poor adherence (use of 50% recommended medications; score =0.5). To analyze the adherence to the recommended doses of HF medications the score was calculated for each patient by summing the points: 0 for non-prescription of medication, 0.5 points for use of <50% of target doses and 1 point for the each prescribed medication at =50% target dose.

Results. The score of adherence to guideline-recommended medications was good in 80%, moderate in 16%, and poor in 4% of HF patients. However, at discharge from hospital, the proportion of patients at target doses and = 50% of target doses was low (17.7% and 47% for ACEIs/ARBs, 15% and 42% for BBs, 14% and 35% for ivabradine, respectively). 70% of HF patients were at recommended doses of MRAs. The score of adherence to the recommended doses of HF medications was good in 35%, moderate in 63%, and poor in 2% of HF patients without a tendency for improvement during 12 months of follow-up. Poor adherence to guideline-recommended HF medications and to the recommended doses was associated with significantly higher HF hospitalization rates (HR 1.46, 95% CI, 1.18-1.76, p=0.0001 and HR 1.46, 95% CI, 1.18-1.76, p=0.0001, respectively) (Figure).

Conclusion. Regardless of the prevalence of good scores of physicians’ adherence to guideline-recommended HF medications, in most cases the doses of these agents continue to be suboptimal. Poor adherence to guideline-recommended therapy is associated with a higher rate of HF re-hospitalizations. New educational initiatives improving physicians’ adherence to guidelines are required.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are